Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
© Motta et al.; licensee BioMed Central Ltd. 2012
Received: 24 April 2012
Accepted: 15 June 2012
Published: 15 June 2012
The aim of this study was to explore the effects of HCV co-infection on virological effectiveness and on CD4+ T-cell recovery in patients with an early and sustained virological response after HAART.
We performed a longitudinal analysis of 3,262 patients from the MASTER cohort, who started HAART from 2000 to 2008. Patients were stratified into 6 groups by HCV status and type of anchor class. The early virological outcome was the achievement of HIV RNA <500 copies/ml 4–8 months after HAART initiation. Time to virological response was also evaluated by Kaplan-Meier analysis. The main outcome measure of early immunological response was the achievement of CD4+ T-cell increase by ≥100/mm3 from baseline to month 4–8 in virological responder patients. Late immunological outcome was absolute variation of CD4+ T-cell count with respect to baseline up to month 24. Multivariable analysis (ANCOVA) investigated predictors for this outcome.
The early virological response was higher in HCV Ab-negative than HCV Ab-positive patients prescribed PI/r (92.2% versus 88%; p = 0.01) or NNRTI (88.5% versus 84.7%; p = 0.06). HCV Ab-positive serostatus was a significant predictor of a delayed virological suppression independently from other variables, including types of anchor class. Reactivity for HCV antibodies was associated with a lower probability of obtaining ≥100/mm3 CD4+ increase within 8 months from HAART initiation in patients treated with PI/r (62.2% among HCV Ab-positive patients versus 70.9% among HCV Ab-negative patients; p = 0.003) and NNRTI (63.7% versus 74.7%; p < 0.001). Regarding late CD4+ increase, positive HCV Ab appeared to impair immune reconstitution in terms of absolute CD4+ T-cell count increase both in patients treated with PI/r (p = 0.013) and in those treated with NNRTI (p = 0.002). This was confirmed at a multivariable analysis up to 12 months of follow-up.
In this large cohort, HCV Ab reactivity was associated with an inferior virological outcome and an independent association between HCV Ab-positivity and smaller CD4+ increase was evident up to 12 months of follow-up. Although the difference in CD4+ T-cell count was modest, a stricter follow-up and optimization of HAART strategy appear to be important in HIV patients co-infected by HCV. Moreover, our data support anti-HCV treatment leading to HCV eradication as a means to facilitate the achievement of the viro-immunological goals of HAART.
The introduction of highly-active anti-retroviral therapy (HAART) has determined a dramatic improvement in the management of HIV-1 infection, leading to suppression of HIV viraemia and consequent restoration of the immune function. However, viro-immunological effectiveness of HAART may be hampered by other factors [1–4].
In particular, the impact of co-infection with hepatitis C virus (HCV) on treatment response is still controversial despite the large number of published data. In this respect, co-infection with HCV has a potential great relevance because its prevalence is up to 80% in those who acquired HIV through injection drug use .
Several studies reported a reduced CD4+ T-cell count recovery in patients with HIV and HCV co-infection with respect to patients with HIV alone [6–13]. This conclusion was further supported by a meta-analysis , but was not confirmed by other results [15–17]. Moreover, variable levels of HIV RNA may confound the association of HIV co-infection with CD4+ T-cell count increase. In particular, we need data in patients who obtained early and sustained virological response to minimize the influence of variable levels of HIV replication on the immunological response because the results currently available are inconsistent, with some studies demonstrating a difference  and others disproving it [18, 19].
Regarding virological response, several studies did not demonstrate any significant associations with HCV status [16, 17], however one recent study evaluated time to virological suppression as primary outcome and found that HCV Ab-positivity was associated with a reduced rate of virological suppression at bivariate analysis, but not adjusting for history of intravenous drug use. .
The aim of this study was to explore the effects of HCV co-infection on virological effectiveness and on CD4+ T-cell reconstitution in patients with an early and sustained virological response after HAART. Also, stratified analyses were conducted by anchor drug --i.e. the antiretroviral drug added as third component to a backbone of nucleoside reverse transcriptase inhibitors-- to explore whether different drug characteristics may have an effect.
Design of the study and cohort used
We conducted an analysis on naïve patients enrolled in the Italian MASTER (Management of standardized antiretroviral therapy) cohort who started first line HAART containing protease inhibitors (either boosted by ritonavir - PI/r - or not boosted) or non-nucleoside reverse transcriptase inhibitor (NNRTI) from 1st January 2000 to 31st December 2008. Patients were stratified into 6 groups according to the type of anchor class received (PI, PI/r or NNRTI) and HCV Ab status (positive or negative).
The MASTER cohort is a longitudinal multicenter cohort consisting of a general HIV patient population in nine referral centres throughout Italy (http://www.mastercohort.it). The distinguishing characteristic of this cohort is that data are compiled in a common electronic chart (Health & Notes 3.5®, Healthware S.p.A., Naples, Italy) in use in the participating centres. Data are recorded over a standardized time-scale every 3 months, with merging and data cleaning performed at the coordinating centre every 6 months. Subjects gave written informed consent for participation in the observational cohort, and each site obtained approval by its Ethics Committee.
The main virological outcome was the achievement of early virological response, i.e., HIV RNA <500 copies/ml within 8 months from HAART initiation (values included between 4 and 8 months, closest to month 8, were considered). This limit of detection for undetectability was chosen because it was the highest value ever used in the clinical centers participating to the MASTER cohort during the time frame of the study. The main virological outcome was assessed both through intent-to-treat (ITT) and on treatment (OT) analyses. At ITT analysis, all patients were included even if they changed drugs used as anchor (PI or PI/r to NNRTI and vice-versa, or PI to PI/r and vice-versa); at OT analysis, only patients who did not change class therapy were considered. A logistic model was performed with undetectable HIV RNA as dependent variable and HIV RNA at baseline and HCV Ab reactivity as independent variables.
We also assessed the rate of patients with HIV RNA <500 copies/ml by Kaplan Meier survival curves over a mean length of follow-up of 52 (SD: 33) months.
Possible predictors of time to virological suppression were assessed through Cox regression analysis considering as independent variables either baseline factors (age at HAART initiation, gender, risk factors for HIV acquisition, history of AIDS diagnosis, HIV RNA, HCV Ab status, calendar year at HAART) or time dependent factors (CD4+ T-cell count, type of anchor class). All the variables were input in a multivariate model. The proportional hazards assumption was checked by determining whether plotting the log [−log(survival)] curve against survival time resulted in parallel lines for each covariate. Moreover, scaled Schoenfeld residuals were plotted on functions of time and tested for a non-zero slope.
For the study of early immunological response, we used patients who obtained HIV RNA <500 copies/ml within 8 months from HAART initiation (values included between 4 and 8 months, closest to month 8, were considered) and CD4+ T-cell count was assessed in the same time frame (values closest to month 8 were used). In these patients, two immunological outcomes were evaluated: (i) CD4+ T-cell increase by ≥100/mm3 from baseline (categorical outcome); (ii) absolute CD4+ T-cell change (continuous outcome). For the categorical outcome, a bivariate logistic analysis was performed with HIV RNA at baseline and HCV Ab status (positive or negative) used as independent variables. For the continuous outcome, ANCOVA model was performed. In this analysis, CD4+ T-cell change from baseline was the dependent variable, HIV RNA value at baseline was the covariate, and HCV Ab reactivity was the fixed effect.
For the study of late immunological response, the same patients were studied until HIV RNA remained undetectable (<500 copies/ml), patients were lost to follow-up (lack of exams for ≥6 months), or died. Moreover, analyses were truncated when <30% patients were under observation to avoid inconsistent results due to an insufficient number of patients under study.
We studied the immunological response as absolute CD4+ T-cell count increase adjusted for CD4+ T-cell count at baseline. First, ANCOVA model was performed in order to assess differences between HCV Ab-positive and HCV Ab-negative patients, stratified by anchor class at month 24 after HAART initiation. In this analysis, baseline CD4+ T-cell count and HCV Ab reactivity were fixed effects. Second, ANCOVA models were used with absolute CD4+ T-cell count increase as dependent variables to assess predictors at months 12 and 24. At this analysis, we considered as possible predictors: age at HAART initiation, gender, risk factors for HIV acquisition, history of AIDS diagnosis, HIV RNA, CD4+ T-cell count, HCV Ab status, calendar year at HAART and type of anchor class.
Additional statistical notes
Descriptive statistics were calculated for quantitative variables (mean, standard deviation – SD, median, minimum and maximum) and qualitative variables (absolute and percent frequencies) as appropriate. Ninety-five percent confidence intervals (95%CI) were calculated for appropriate cases. Variables were compared by means of F test from ANOVA model or χ2 test in case of quantitative or qualitative variables, respectively.
All analyses have been performed using the statistical software package SAS 9.2 (SAS Inc. Cary, NC). All p value were two-tailed and considered significant if <0.05.
Patients’ characteristics at baseline
(n = 146)
(n = 208)
Ab + PI + r
(n = 365)
PI + r
(n = 1059)
Ab + NNRTI
(n = 352)
(n = 1132)
Age at cohort entry, years [Mean (SD)]
Age at HAART initiation, years [Mean (SD)]
Calendar year at HAART [Median (range)]
Risk factors for HIV acquisition [N(%)]
AST, IU/L [Mean (SD)]
ALT, IU/L [Mean (SD)]
Serum creatinine, mg/dL[Mean (SD)]
Cholesterolaemia, mg/dL [Mean (SD)]
Nadir of CD4+ T-cells, cells/mm3 [Mean (SD)]
AIDS diagnosis [N (%)]
CD4+ T-cell count, cells/mm3 [Mean (SD)]
HIV-1 RNA, copies/ml [Mean (SD)]
Virological analysis (patients stratified by HCV serostatus and classes of anchor drugs)
The early virological response rate was significantly higher in HCV Ab-negative than in HCV Ab-positive patients. The ITT analysis showed that, in the overall population, 87.8% patients achieved virological success. In patients receiving a PI (N = 354), those who did not reach an early virological response were 34/146 (23.3%) among HCV Ab-positive patients versus 52/208 (25%) HCV Ab-negative patients (p = 0.66); among the 1424 patients treated with PI/r, 44/365 (12%) HCV Ab-positive versus 83/1059 (7.8%) HCV Ab-negative patients did not reach the virological response (OR 0.612, 95%CI 0.416 to 0.903, p = 0.01); in the NNRTI group (N = 1484) those who did not achieve the virological response were 54/352 (15.3%) HCV Ab-positive versus 130/1132 (11.5%) HCV Ab-negative patients (OR 0.717, 95%CI 0.509 to 1.01, p = 0.06). Also at OT analysis, significant differences between HCV Ab-positive and HCV Ab-negative patients emerged only in those treated with PI/r (OR 0.582, 95%CI 0.389 to 0.869, p = 0.01), and in those treated with NNRTI (OR 0.618, 95%CI 0.419 to 0.912, p = 0.02).
Predictors of time to achieve virological suppression
Immunological analysis (patients stratified by HCV serostatus and classes of anchor drugs)
For the early immunological response, achievement of CD4+ T-cell increase ≥100/mm3 within 8 months from HAART initiation was evaluated among patients with a virological response. In this analysis, 2,682 patients who had values of CD4+ T-cell count both at baseline and after 4–8 months were considered. Among patients receiving a PI (N = 239) there were not significant differences between mono- and co-infected patients at bivariate analysis (60.8% versus 65.5%, p = 0.35). Conversely, in the PI/r group (N = 1,220) HCV Ab-positive patients had a lower probability to reach the outcome than HCV Ab-negative patients (62.2% versus 70.9%, OR 0.662, 95%CI 0.502 to 0.872, p = 0.003). Also, among NNRTI-receiving patients (N = 1,223), CD4+ T-cell count increase ≥100/mm3 was less likely to be achieved by HCV Ab-positive patients (63.7% versus 74.7%, OR 0.595, 95%CI 0.445 to 0.797, p < 0.001). A significant difference in CD4+ T-cell count increase was also found in this group at ANCOVA when absolute CD4+ T-cell count increase was analyzed as continuous measure (−36.8/mm3, 95%CI −53.6 to −20.1, p < 0.001).
Predictors of CD4+ T-cell count recovery
Predictors of immune recovery (absolute CD4+ T-cell increase from baseline after HAART)
Age at HAART initiation [x10-yrs]
AIDS [no vs. yes]
CD4+ [x50 cells/mm3]
HIV RNA [x1 log10]
HCV + vs HCV-
PI vs PI/r
HCV Ab-positive status appeared to predict smaller CD4+ T-cell increase after 12 months of HAART (p = 0.005), independently from age at HAART onset, and HIV RNA at baseline, both significant predictors of this outcome (p = 0.002 and <0.001, respectively). However, after 24 month of HAART, the impact of HCV Ab status disappeared.
In this study, the possible impact of HCV co-infection on viro-immunological effectiveness of different HAART regimens was explored both in the early and in the late follow-up and using both a stratified and a multivariable analysis.
In the overall population we found that 88% patients reached HIV RNA suppression within months 4–8 months from initiation of HAART at ITT analysis. However, percentages differed by HCV co-infection and by anchor class received. In fact, HCV Ab-positive patients obtained HIV RNA suppression less likely than HIV mono-infected patients, though this difference was greater in those treated with PI/r (88% versus 92.2%) and NNRTI (84.7% versus 88.5%) than in those treated with PI (76.7% versus 75%). It is possible that this finding reflects a treatment adherence phenomenon. In fact, on one hand, if one assumes that HCV Ab-positivity is a proxy for a negative behavior related to IVDU, with a negative influence on treatment adherence [5, 21], the difference in virological suppression would be magnified in patients who received more complex regimens (such as the PI/r most frequently used at the time of the study) . On the other hand, in patients prescribed less potent regimens (such as PI), differences between the two groups could have been diluted. Indeed, the rate of treatment success in these patients was the lowest.
However, when predictors of HIV RNA response were investigated, HCV co-infection appeared to be a negative predictor independently from IVDU, suggesting that the effects of these two variables were not entirely overlapping. This may be due either to HCV co-infection “per se” (probably affecting the immune control of HIV replication) or to adherence as unmeasured variable because HCV co-infected patients may have been less adherent to treatment even though they were not IVDU. Further bio-psycho-social investigations are needed to understand the complex relationship between HCV co-infection, the role of adherence behaviors and IVDU as risk factor.
Regarding the other predictors of virological success, the positive impact of aging (possibly reflecting better adherence in older patients) is not new [23, 24], as well as the positive impact of more recent calendar years, possibly reflecting a significant improvement in the drug regimens and in the overall standard of care [25, 26].
We found a positive impact of higher CD4+ T-cell count as a protective variable for achieving HIV RNA suppression. It is possible that the immune system (either at baseline or reconstituted by HAART) has a role in better controlling HIV replication. If this is the case, our results point to earlier HAART initiation as a means to preserve immune system so that virological suppression is more frequent. But also the lack of virological suppression (or virological suppression in presence of suboptimal adherence), may be a cause rather than a consequence of lower CD4+ count, supporting the importance of a continuing assessment of treatment adherence, especially in HIV/HCV co-infected patients who appear to be disadvantaged.
Regarding the immunological outcomes, reactivity for HCV Ab was associated with a lower probability of obtaining ≥100 CD4+ T-cell count increase within 8 months from HAART initiation and with a smaller CD4+ T-cell count recovery up to 12 months in a multivariable analysis. It has been hypothesized that CD4+ T-cell depletion might result from ongoing cell activation and apoptosis driven by HCV  and therefore HCV could lower the CD4+ T-cell recovery through a direct pathogenic effect on lymphocytes even after HAART . Our results, together with this interpretation, suggest that it is important to treat HCV infection aimed at obtaining its eradication, not only with the main goal of treating liver disease but also as a means to improve the viro-immunological outcomes of HAART, especially early upon its inception.
Greub et al. studied a group of 1596 patients (33% of them were HCV Ab-positive) with sustained HIV RNA <400 copies/ml and found that HCV Ab-positive subjects had an impaired CD4+ T-cell recovery in the long term . By contrast, data from Kaufmann’s studies did not show any significant difference in CD4+ T-cell recovery when comparing HCV Ab-positive and HCV Ab-negative patients . Our results suggest that, even though HCV infection may have an impact in the short term (either because immune activation has not yet been down-regulated or because HIV RNA is less effectively controlled early upon HAART), a more prolonged undetectability of HIV RNA may eventually counteract the apparent disadvantage occurring in HCV co-infected patients.
The present study suffers from limitations: first, HCV RNA was not considered, therefore patients with HCV Ab-positive but negative HCV RNA may have been included in the analysis, even if patients treated with anti-HCV drugs were excluded with the aim to reduce this possible bias. Second, HCV genotypes were not considered. A small study found that, among 171 HIV/HCV co-infected patients, those infected by HCV genotype 3 had inferior CD4+ T-cell increase after 12 months of follow-up . However data from Antonucci et al.  did not find any correlation between HCV genotypes and immune-reconstitution in a cohort of 284 antiretroviral naïve patients. Therefore, further studies are needed to investigate the possible role of HCV genotypes on immune reconstitution in larger cohorts of patients over a longer follow-up. Third, other possible confounders such as severity of liver disease were not measured. Fourth, a <500 copies/ml cut-off for undetectability was considered. It is possible that persistent HIV replication below this cut-off may have had an impact on immune-reconstitution but this effect was not captured in our analysis.
In conclusion, the analysis of virological response suggests that HCV Ab-positive patients need focused interventions to maximize the effectiveness of HAART, especially early upon HAART initiation. Moreover, an higher CD4+ T-cell count predicted better virological control suggesting that preservation of immune functions is important not only to prevent clinical complications but also as a means to better control HIV replication. Thus, earlier HAART initiation is supported, especially in HIV/HCV co-infected subjects whose viro-immunological response may be compromised relative to HIV mono-infected patients. Lastly, it is possible that HCV eradication through specific treatments is beneficial not only for the main goal of treating liver disease but also for the viro-immunological effectiveness of HAART.
This work was partially supported by Janssen Cilag SpA through an unrestricted grant and by NEAT (Network for Excellence in Antiretroviral Treatment) funded by the European Commission (Project number: LSHP-CT-2006-037570).
Statistical analysis was performed by CROS NT (http://www.cros.it/).
The Italian MASTER Cohort is a large national project involving the major centers providing care to HIV/AIDS patients and includes the following doctors: F. Castelli, G. Carosi, C. Torti, E. Quiros, P. Nasta, G. Paraninfo, E. Focà, Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy; R. Cauda S. Di Giambenedetto, M. Fabbiani, M. Colafigli, Catholic University of Sacred Heart, Rome, Italy; F. Maggiolo Ospedali Riuniti, Bergamo, Italy; A. Scalzini, F. Castelnuovo, I. El Hamad, Spedali Civili di Brescia, Brescia, Italy; F. Mazzotta, S. Locaputo, N. Marino, P. Pierotti M. Di Pietro, C. Blè, F. Vichi, “S. Maria Annunziata” Hospital, Florence, Italy; L. Sighinolfi, “S. Anna” Hospital, Ferrara, Italy; G. Angarano, N. Ladisa, L. Monno, P. Maggi, Policlinico di Bari, Bari, Italy; A. Pan, S. Costarelli, Istituti Ospitalieri, Cremona, Italy; A. Gori, G. Lapadula, M. Airoldi, N Squillace, A. Soria, A. Muscatello, Ospedale S. Gerardo, Monza, Italy; M. Puoti, Ospedale Niguarda Cà Granda Milano, Italy; P. Viale, V. Colangeli, M. Borderi, Policlinico S. Orsola Malpighi, Bologna, Italy.
This work has been presented in part to the “6th IAS Conference on HIV pathogenesis, treatment and prevention”, Rome, Italy, 17–20 July 2011, (Abstract TUPE-106).
We would like to thank all patients participating in the MASTER Cohort Study, all doctors and study nurse involved, and the datacentre. We also wish to thank Ms. Francesca Brognoli, Dr. Cristina Minardi for kind technical assistance.
- Furber AS, Maheswaran R, Newell JN, Carroll C: Is smoking tobacco an independent risk factor for HIV infection and progression to AIDS? A systemic review. Sex Transm Infect. 2007, 83: 41-46.PubMed CentralView ArticlePubMedGoogle Scholar
- Operskalski EA, Kovacs A: HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011, 8: 12-22. 10.1007/s11904-010-0071-3PubMed CentralView ArticlePubMedGoogle Scholar
- Zellan J, Augenbraun M: Syphilis in the HIV-infected patient: an update on epidemiology, diagnosis, and management. Curr HIV/AIDS Rep. 2004, 1: 142-147. 10.1007/s11904-004-0021-zView ArticlePubMedGoogle Scholar
- Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D: Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010, 50: 1288-1299. 10.1086/651686View ArticlePubMedGoogle Scholar
- Bollepalli S, Mathieson K, Bay C, Hillier A, Post J, Van Thiel DH, Nadir A: Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients. Sex Transm Infect. 2007, 34: 367-370.Google Scholar
- Carlos Martín J, Castilla J, López M, Arranz R, González-Lahoz J, Soriano V: Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials. 2004, 5: 125-131. 10.1310/YFV8-FE5K-5LN9-DQ4CView ArticlePubMedGoogle Scholar
- Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD: Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis. 2005, 40: e101-e109. 10.1086/430445View ArticlePubMedGoogle Scholar
- Braitstein P, Zala C, Yip B, Brinkhof MWG, Moore D, Hogg RS, Montaner JSG: Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis. 2006, 193: 259-268. 10.1086/498908View ArticlePubMedGoogle Scholar
- Carmo RA, Guimarães MDC, Moura AS, Neiva AM, Versiani JB, Lima LV, Freitas LP, Rocha MOC: The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients. Braz J Infect Dis. 2008, 12: 173-179.View ArticlePubMedGoogle Scholar
- Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000, 356: 1800-1805. 10.1016/S0140-6736(00)03232-3View ArticlePubMedGoogle Scholar
- De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D’Arminio Monforte A: Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002, 162: 2125-2132. 10.1001/archinte.162.18.2125View ArticlePubMedGoogle Scholar
- Santin M, Mestre M, Shaw E, Barbera MJ, Casanova A, Niubo J, Bolao F, Podzamczer D, Gudiol F: Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. Eur J Clin Microbiol Infect Dis. 2008, 27: 65-73.View ArticlePubMedGoogle Scholar
- Weis N, Lindhardt BO, Kronborg G, Hansen A-BE, Laursen AL, Christensen PB, Nielsen H, Moller A, Sorensen HT, Obel N: Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis. 2006, 42: 1481-1487. 10.1086/503569View ArticlePubMedGoogle Scholar
- Miller MF, Haley C, Koziel MJ, Rowley CF: Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005, 41: 713-720. 10.1086/432618View ArticlePubMedGoogle Scholar
- Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD: Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr. 2009, 50: 457-463. 10.1097/QAI.0b013e318198a0e1View ArticlePubMedGoogle Scholar
- Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005, 192: 992-1002. 10.1086/432762View ArticlePubMedGoogle Scholar
- Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT: Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006, 20: 1171-1179. 10.1097/01.aids.0000226958.87471.48View ArticlePubMedGoogle Scholar
- Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M: CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003, 163: 2187-2195. 10.1001/archinte.163.18.2187View ArticlePubMedGoogle Scholar
- Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005, 41: 361-372. 10.1086/431484View ArticlePubMedGoogle Scholar
- Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JSG, Rourke SB, Smieja M, Tsoukas C, Hogg RS: Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. HIV Med. 2011, 12: 352-360. 10.1111/j.1468-1293.2010.00890.xView ArticlePubMedGoogle Scholar
- Staples CT, Rimland D, Dudas D: Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999, 29: 150-154. 10.1086/520144View ArticlePubMedGoogle Scholar
- Goulet JL, Fultz SL, McGinnis KA, Justice AC: Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS. 2005, 19 (Suppl 3): S99-S105. 10.1097/01.aids.0000192077.11067.e5View ArticlePubMedGoogle Scholar
- Sabin CA, Smith CJ, D’ Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J: Response to combination antiretroviral therapy: variation by age. AIDS. 2008, 22: 1463-1473.View ArticlePubMedGoogle Scholar
- Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA: Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS. 2008, 22: 2331-2339. 10.1097/QAD.0b013e32831883f9PubMed CentralView ArticlePubMedGoogle Scholar
- Sighinolfi L, Torti C, Zeni C, Ghinelli F, Suter F, Maggiolo F, Antinori A, Antonucci G, Castelnuovo F, Ladisa N, Migliorino M, Novati S, De Luca A, Lo Caputo S, Paraninfo G, Tinelli C, Carosi G: Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study. Infection. 2008, 36: 244-249. 10.1007/s15010-007-7227-0View ArticlePubMedGoogle Scholar
- Prosperi MCF, Cozzi-Lepri A, Antinori A, Cassola G, Torti C, Ursitti MA, Pellizzer GP, Giacometti A, D’ Arminio Monforte A, De Luca A: Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998–2008. HIV Med. 2011, 12: 174-182. 10.1111/j.1468-1293.2010.00866.xView ArticlePubMedGoogle Scholar
- Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ: “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008, 9: 238-246. 10.1310/hct0904-238View ArticlePubMedGoogle Scholar
- Núñez M, Soriano V, López M, Ballesteros C, Cascajero A, González-Lahoz J, Benito JM: Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. Clin Infect Dis. 2006, 43: 1209-1212. 10.1086/508355View ArticlePubMedGoogle Scholar
- Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, Cianciara J, Rakela J: Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis. 2000, 181: 442-448. 10.1086/315283View ArticlePubMedGoogle Scholar
- Seminari E, Tinelli C, Ravasi G, Ripamonti D, Ladisa N, Marino N, Sighinolfi L, Mondello P, Migliorino M, Carosi G, Maserati R: Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res. 2010, 8: 186-193. 10.2174/157016210791111070View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.